TherapeuticsMD (TXMD) Given a $11.00 Price Target at JPMorgan Chase & Co.  Anthony Miller | Aug 17th, 2018
TherapeuticsMD (NASDAQ:TXMD) received a $11.00 target price from JPMorgan Chase & Co. in a note issued to investors on Wednesday. The brokerage currently has a "buy" rating on the stock. JPMorgan Chase & Co.'s target price indicates a potential upside of 98.20% from the stock's current price.
TXMD has been the topic of several other research reports. ValuEngine lowered TherapeuticsMD from a "buy" rating to a "hold" rating in a research report on Friday, June 1st. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a "buy" rating in a research report on Friday, August 10th. Oppenheimer set a $12.00 target price on TherapeuticsMD and gave the company a "buy" rating in a research report on Monday, July 30th. Zacks Investment Research lowered TherapeuticsMD from a "hold" rating to a "sell" rating in a research report on Wednesday, April 25th. Finally, BidaskClub upgraded TherapeuticsMD from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 26th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. TherapeuticsMD presently has a consensus rating of "Buy" and a consensus target price of $14.75. Get TherapeuticsMD alerts:
Shares of TherapeuticsMD stock opened at $5.55 on Wednesday. TherapeuticsMD has a one year low of $4.34 and a one year high of $7.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 7.79 and a current ratio of 7.88. The stock has a market cap of $1.21 billion, a P/E ratio of -15.00 and a beta of 1.53.
TherapeuticsMD (NASDAQ:TXMD) last announced its earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). TherapeuticsMD had a negative net margin of 582.86% and a negative return on equity of 80.75%. The business had revenue of $3.80 million for the quarter, compared to the consensus estimate of $4.23 million. During the same quarter in the previous year, the company earned ($0.10) EPS. The firm's revenue for the quarter was down 11.6% on a year-over-year basis. equities research analysts expect that TherapeuticsMD will post -0.6 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of TXMD. Fox Run Management L.L.C. acquired a new position in TherapeuticsMD during the 2nd quarter worth approximately $121,000. Beaumont Financial Partners LLC acquired a new position in TherapeuticsMD during the 1st quarter worth approximately $123,000. Xact Kapitalforvaltning AB raised its stake in TherapeuticsMD by 96.3% during the 1st quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company's stock worth $155,000 after buying an additional 15,600 shares during the period. Affiance Financial LLC acquired a new position in TherapeuticsMD during the 2nd quarter worth approximately $156,000. Finally, Barclays PLC raised its stake in TherapeuticsMD by 33,787.3% during the 1st quarter. Barclays PLC now owns 37,276 shares of the company's stock worth $182,000 after buying an additional 37,166 shares during the period. 72.13% of the stock is currently owned by institutional investors and hedge funds.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Recommended Story: Stock Symbol TherapeuticsMD TherapeuticsM